IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Cytotoxic T-Cell Exhaustion and Suppression in Tumor Microenvironment

T cell exhaustion and tumour microenvironment

[1]Kamireddy Pranavi, [2] Cherukuri Pooja, [3] Saidunnisa Begum, [4]Kommalapati Vatsalya,

[5] Poosarla Chandrashekar

[1] Under graduate student, [2] Under graduate student, [3] Intern, [4] Assistant professor [5] Professor

Department of Oral &Maxillofacial Pathology, SIBAR Institute of Dental Sciences, Guntur, Andhra Pradesh, India.

Abstract :

$CD8^+$ T cells, also known as cytotoxic T lymphocytes, play a vital role in defending the body against viral infections and cancer by killing infected or abnormal cells. However, in chronic infections and tumors, these cells are exposed to continuous stimulation, leading to a state called exhaustion. Exhausted $CD8^+$ T cells lose their ability to multiply, produce cytokines, and kill target cells. This condition is marked by the expression of inhibitory receptors and metabolic dysfunction. The tumor microenvironment (TME) adds further suppression by limiting nutrients and releasing inhibitory signals. Recent strategies such as immune checkpoint blockade, cytokine therapy, metabolic reprogramming, and adoptive T cell therapy aim to restore T cell function and improve immune response. Understanding and reversing $CD8^+$ T cell exhaustion is crucial for developing better treatments for cancer and chronic infections.

Index Terms : **$CD8^+$ T cells, T cell exhaustion, chronic infection, cancer immunotherapy, tumor microenvironment, PD-1, adoptive cell therapy, cytokines.**

I. INTRODUCTION

CD8 T cells aka cytotoxic T lymphocytes play a major role in adaptive or acquired immunity especially against viral infections and tumour cells. They are activated when the T Cell Receptor (TCR) binds to a specific antigen bound to class l MHC presented by APCs (Antigen Presenting Cells) [(1)] .These cells upon activation, differentiate into Memory CD8 T cells – which help in maintaining long term immunity and Effector CD8 T cells – which find and kill the harmful cells by secreting cytokines (INF – gamma, TNF – a), perforins and granzymes[(2).] For our immune system to work effectively and efficiently, these CD8 T cells need to stay active and strong. But in cases where there are chronic infection/ cancers, these cells are stimulated repeatedly for prolonged period of time and hence become tired and less active – this is what we call "CD8 T cell Exhaustion" This dysfunctional state of exhaustion is marked by high and sustained expression of many inhibitory surface receptors[(3).]

T cell exhaustion presents a major barrier to effective immune control because it allows diseases like cancer or chronic infections to keep growing. That is why understanding cellular, molecular, and metabolic basis of CD8 T cell exhaustion is important – not just to understand how the immune system fails, but also to find ways to help these cells recover and fight back [(4).]This review seeks to summarize current insights into the biology of exhausted CD8 Tells, the mechanisms driving this state, and discuss how reprogramming these cells reinvigorate anti-tumour immunity.

The Biology of CD8 T cells Exhaustion

CD8⁺ T cell exhaustion is a state of progressive dysfunction that arises when these immune cells are exposed to persistent antigen stimulation, as seen in chronic infections and cancer[5] Prolonged activation leads to a gradual loss of their ability to proliferate, produce key cytokines like IFN-γ and TNF-α, and kill infected or malignant cells [2]. A defining feature of exhausted T cells is the sustained expression of multiple inhibitory receptors such as PD-1, TIM-3, and LAG-3, which act as molecular brakes and suppress T cell activity[6] [7] [8]. Exhaustion develops in stages—early or progenitor exhausted T cells retain partial function and responsiveness to immunotherapy, while terminally exhausted T cells exhibit severe dysfunction and limited ability to recover. Internally, transcription factors like TOX and NR4A reprogram the gene expression of CD8⁺ T cells, locking them into an exhausted state that is often reinforced by stable epigenetic changes[9] [10]. Although these cells are not immediately eliminated, their lifespan is marked by prolonged survival in a functionally impaired state, making it challenging for the immune system to effectively eliminate chronic infections or tumors without therapeutic intervention.

Metabolic Dysregulation in Exhausted CD8 T Cells

CD8⁺ T cell function is closely linked to their metabolic state, which undergoes significant changes during activation, memory formation, and exhaustion. Under normal immune conditions, activated CD8⁺ T cells rely on aerobic glycolysis to rapidly produce energy and biosynthetic materials necessary for proliferation, cytokine production, and cytotoxic activity. However, in chronic infections or cancer, prolonged antigen exposure and a suppressive microenvironment disrupt this metabolic balance. Exhausted T cells often exhibit mitochondrial dysfunction, reduced glucose uptake, and impaired oxidative phosphorylation, leading to an insufficient energy supply[11]. These metabolic deficiencies hinder the cells' ability to sustain effector functions and contribute to their dysfunctional state. Dysregulation of key metabolic regulators such as mTOR, AMPK, and HIF-1α further exacerbates exhaustion, locking CD8⁺ T cells in a state of low energy and reduced responsiveness. Addressing these metabolic impairments offers a potential strategy to rejuvenate exhausted T cells and enhance their therapeutic effectiveness in chronic disease settings[12].

Tumor Microenvironment (Tme): A Hub Of Suppression

The tumor microenvironment (TME) is a dynamic and immunosuppressive setting that plays a central role in the exhaustion and dysfunction of CD8⁺ T cells during cancer progression[13]. It comprises not only malignant tumor cells but also a variety of non-malignant components, including stromal cells, fibroblasts, endothelial cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). These elements create a hostile environment by producing immunosuppressive cytokines such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), which directly inhibit T cell proliferation and effector function. In addition to these suppressive signals, the TME exhibits extreme metabolic stress. Rapidly proliferating tumor cells outcompete immune cells for essential nutrients like glucose and amino acids, while accumulating metabolic byproducts such as lactic acid. This nutrient deprivation impairs CD8⁺ T cell metabolism, reducing their ability to perform glycolysis and mitochondrial respiration—processes vital for their cytotoxic activity[14] [15]. Hypoxia, or oxygen deficiency in the tumor tissue, further exacerbates this stress by stabilizing hypoxia-inducible factor-1α (HIF-1α), which alters gene expression and drives T cells toward a dysfunctional phenotype. The TME also expresses high levels of immune checkpoint ligands like PD-L1, which interact with inhibitory receptors (e.g., PD-1) on CD8⁺ T cells, reinforcing exhaustion and blocking activation signals[16]. Physical barriers such as dense extracellular matrix and abnormal vasculature limit T cell infiltration into tumor cores, further restricting their antitumor capabilities. Overall, the TME functions as a "hub of suppression" by combining metabolic constraints, inhibitory signals, and physical barriers. It not only limits CD8⁺ T cell function but also actively shapes them into an exhausted state, making it a major obstacle to successful cancer immunotherapy. Understanding and targeting the TME is critical to reinvigorating effective anti-tumour immune responses[13].

Approaches to Reinvigorate Exhausted CD 8 T cells

When CD8⁺ T cells become exhausted due to long-term exposure to infections or cancer, their ability to fight harmful cells weakens. Scientists are working on ways to "wake up" these tired cells and help them work properly again. One major approach is immune checkpoint blockade. This involves using special drugs (like anti-PD-1 or anti-CTLA-4 antibodies) that block the "off" signals on T cells, allowing them to become active again and attack cancer or infected cells. Another method focuses on boosting cell energy[16]. Exhausted T cells don't get enough fuel to work, so researchers try to improve their metabolism using medicines that restore energy production and improve mitochondrial function. Giving cytokines (like IL-2 or IL-15) can also help by supporting T cell survival and growth. Adoptive cell therapy (ACT) is another strategy, where healthy or engineered T cells are grown in labs and put back into the body to fight diseases more effectively. Lastly, changing the tumor environment by reducing harmful substances and

improving oxygen and nutrients helps T cells stay strong. Combining these approaches gives the best results in helping exhausted $CD8^+$ T cells recover and fight back against chronic infections or cancer[5]

Future Directions

Although research on $CD8^+$ T cell exhaustion has advanced, several gaps remain. Future studies aim to identify clear biomarkers to distinguish between reversible and terminally exhausted cells, allowing for more targeted therapies. Combining immune checkpoint inhibitors with metabolic or cytokine therapies shows promise, but optimal combinations need exploration. Understanding the genetic and epigenetic mechanisms behind exhaustion could help safely reprogram these cells. Additionally, more insight is needed into how different diseases and microenvironments affect exhaustion. Ensuring safety, long-term benefits, and access to new treatments will be key to successfully harnessing exhausted T cells for lasting immunity.

CONCLUSION

$CD8^+$ T cell exhaustion happens when these immune cells get overworked during long-term infections or cancer. They become weak, stop working properly, and can't kill harmful cells. Scientists are finding ways to bring these tired cells back to life. Treatments like immune checkpoint blockers, energy-boosting drugs, helpful cytokines, and lab-grown T cells can help them recover. Changing the tumor environment also helps these cells work better. But more research is needed to know which cells can be fixed and which can't. In the future, better treatments can be made by understanding how these cells get exhausted and how to repair them.

REFERENCES

1. Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther. 2023 Jun 19;8(1):235. doi: 10.1038/s41392-023-01471-y. PMID: 37332039; PMCID: PMC10277291.
2. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015 Aug;15(8):486-99. doi: 10.1038/nri3862. PMID: 26205583; PMCID: PMC4889009.+
3. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009 Jan;10(1):29-37. doi: 10.1038/ni.1679. Epub 2008 Nov 30. PMID: 19043418; PMCID: PMC2605166.
4. Abdel-Hakeem MS. Editorial: T cell exhaustion; mechanisms of induction, modulation, and recovery. Front Immunol. 2023 Jan 5;13:1122530. doi: 10.3389/fimmu.2022.1122530. PMID: 36685510; PMCID: PMC9851039.
5. Laura M. McLane et al, CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer,Annual review,2019, Vol. 37:457-495
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. PMID: 22437870; PMCID: PMC4856023.
7. Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A. A transcriptionally and functionally distinct $PD\text{-}1^+$ $CD8^+$ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11. PMID: 29892065; PMCID: PMC6110381.
8. Utzschneider DT, Legat A, Fuertes Marraco SA, Carrié L, Luescher I, Speiser DE, Zehn D. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol. 2013 Jun;14(6):603-10. doi: 10.1038/ni.2606. Epub 2013 May 5. PMID: 23644506.,
9. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, Eisenberg V, Wohlleber D, Steiger K, Merkler D, Delorenzi M, Knolle PA, Cohen CJ, Thimme R, Youngblood B, Zehn D. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019 Jul;571(7764):265-269. doi: 10.1038/s41586-019-1326-9. Epub 2019 Jun 17. PMID: 31207605.
10. Mani N, Andrews D, Obeng RC. Modulation of T cell function and survival by the tumor microenvironment. Front Cell Dev Biol. 2023 May 18;11:1191774. doi: 10.3389/fcell.2023.1191774. PMID: 37274739; PMCID: PMC10232912.
11. Yang MQ, Zhang SL, Sun L, Huang LT, Yu J, Zhang JH, Tian Y, Han CB, Ma JT. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer. 2024 Nov 19;23(1):260. doi: 10.1186/s12943-024-02175-9. PMID: 39563438; PMCID: PMC11575104.

12. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity. 2016 Aug 16;45(2):374-88. doi: 10.1016/j.immuni.2016.07.009. Epub 2016 Aug 2. Erratum in: Immunity. 2016 Sep 20;45(3):701-703. doi: 10.1016/j.immuni.2016.08.009. PMID: 27496732; PMCID: PMC5207350.
13. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020 Aug 17;30(16):R921-R925. doi: 10.1016/j.cub.2020.06.081. PMID: 32810447; PMCID: PMC8194051.
14. De Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. *Cancer Cell*, *41*(3), 374-403. https://doi.org/10.1016/j.ccell.2023.02.016
15. Mayer, S., Milo, T., Isaacson, A., Halperin, C., Miyara, S., Stein, Y., Lior, C., Tzahor, E., Mayo, A., & Alon, U. (2023). The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. *Nature Communications*, *14*(1), 1-17. https://doi.org/10.1038/s41467-023-41518-w
16. Wang, Q., Shao, X., Zhang, Y., Zhu, M., C. Wang, F. X., Mu, J., Li, J., Yao, H., & Chen, K. (2023). Role of tumor microenvironment in cancer progression and therapeutic strategy. *Cancer Medicine*, *12*(10), 11149-11165. https://doi.org/10.1002/cam4.5698